Dark

CLNN
Clene Inc. Common Stock
stock NASDAQ

At Close

May 22, 2025 3:59:30 PM EDT

2.47USD-1.200%(-0.03)129,403

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 22, 2025 8:04:30 AM EDT

2.41USD-3.600%(-0.09)1,400

After-hours

May 22, 2025 4:50:30 PM EDT

2.48USD+0.405%(+0.01)300

OverviewHistoricalExchangesShortsNews

Jan 18, 2022

07:22AM EST Clene Nanomedicine's Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment In COVID-19 Trial Benzinga

07:00AM EST -- Topline data is expected in 1H 2022 -- Trial is evaluating acutely symptomatic, non-hospitalized COVID-19 patients in Brazil -- CNM-ZnAg is a proprietary zinc-silver ionic solution that has demonstrated both antiviral and antibacterial activity. GlobeNewswire Inc

Dec 15, 2021

07:22AM EST Clene Nanomedicine Announces It Has Validated Key Patents Granted By European Patent Office Benzinga

07:00AM EST Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022 GlobeNewswire Inc

Dec 13, 2021

07:00AM EST -- Clene Nanomedicines Maryland facility is among the projects and activities awarded funding -- The manufacturing expansion is in preparation for anticipated commercialization GlobeNewswire Inc

Dec 10, 2021

07:05AM EST Clene Reports Its Nanomedicine Segment To Present RESCUE-ALS Phase 2 Data In Late-Breaking Session At Int'l. Symposium On Amyotrophic Lateral Sclerosis Dec. 10 At 1:05 p.m. EST Benzinga

07:00AM EST Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in GlobeNewswire Inc

Dec 7, 2021

07:00AM EST Clene Nanomedicines RESCUE-ALS Phase 2 Results GlobeNewswire Inc

Dec 1, 2021

07:00AM EST -- CNM-Au8 has favorable impact on progression of ALS as measured by joint rank comparison of combined survival and ALSFRS-R change a clinically meaningful endpoint recommended by the FDA -- CNM-Au8 showed consistent efficacy across limb and bulbar onset participants for ALS disease progression and the proportion with less than a 6-point decline on the ALSFRS-R scale GlobeNewswire Inc

Nov 15, 2021

11:11AM EST Clene Reports Completion Of Patient Enrollment In HEALEY Amyotrophic Lateral Sclerosis Platform Trial Benzinga

08:48AM EST -- Registration trial for CNM-Au8, a gold nanocrystal suspension -- Topline data anticipated 2H 2022 -- Worlds first ALS platform trial accelerating the path to new ALS therapies GlobeNewswire Inc

Nov 9, 2021

11:32AM EST Clene Q3 EPS $0.42 Up From $(0.59) YoY, Sales $110.00K Up From $98.00K YoY Benzinga

07:15AM EST Clene Q3 Net Income $28.9 Mln Or $0.42/Shr Vs Net Loss $10.3 Mln Or $0.59/Shr Last Year RTTNews

07:00AM EST Clene Reports Third Quarter 2021 Operating and Financial Highlights GlobeNewswire Inc

Nov 2, 2021

10:49AM EDT Clene Shares To Resume Trade At 7:30 a.m. EDT Benzinga

10:49AM EDT Clene Reports Its RESCUE-ALS Phase 2 Trial Did Not Meet Primary, Secondary Endpoints Benzinga

10:47AM EDT Clene Shares Halted, News Pending Benzinga

07:00AM EDT Clene Nanomedicine Announces Top-Line Results from Phase 2 GlobeNewswire Inc

Oct 14, 2021

07:12AM EDT Clene Highlights Presentation Of Results From REPAIR-MS Phase 2 Clinical Trials At 37th Congress Of The European Committee For Treatment And Research In Multiple Sclerosis Benzinga

Sep 23, 2021

07:03AM EDT Clene Announces Initiation Of A Second FDA Expanded Access Program With CNM-Au8 For People Living With Amyotrophic Lateral Sclerosis Benzinga

07:00AM EDT Clene Announces Initiation of a Second FDA Expanded Access Program GlobeNewswire Inc

Sep 17, 2021

07:06AM EDT Clene Highlights Presentation Of Phase 2 CNM-Au8 Target Engagement Data At Int'l. Parkinson, Movement Disorder Society Congress Benzinga

07:00AM EDT Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the GlobeNewswire Inc

Sep 9, 2021

07:18AM EDT Clene Completes Final Patient Visit In Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021 Benzinga

07:00AM EDT Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: GlobeNewswire Inc

Aug 31, 2021

07:00AM EDT Clene Inc. (NASDAQ: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced that the Company will present at the following investor conferences in September: GlobeNewswire Inc

Aug 11, 2021

07:19AM EDT Clene Reports 2 New Leases To Materially Expand Manufacturing Capacity Of Its CNM-Au8 Benzinga

07:00AM EDT Clene Enters into Two Leases to Materially Expand Manufacturing GlobeNewswire Inc

Aug 10, 2021

07:21AM EDT Clene Q2 EPS $(0.05) Beats $(0.15) Estimate, Sales $201.00K Beat $60.00K Estimate Benzinga

07:00AM EDT Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8, a gold nanocrystal suspension GlobeNewswire Inc

Aug 5, 2021

07:05AM EDT Clene Reports Top-line Results From Phase 2 REPAIR Clinical Trials In Parkinson's Disease And Multiple Sclerosis Benzinga

07:00AM EDT Achieved a statistically significant increase in the Phase 2 programs primary endpoint(mean change in brain NAD+/NADH ratio) GlobeNewswire Inc

Aug 3, 2021

07:00AM EDT Clene Inc. (NASDAQ: CLNN) along with its subsidiaries Clene and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using nanotechnology to treat energetic failure, today announced that its management team will be presenting at Canaccord Genuity's 41st Annual Growth Conference. GlobeNewswire Inc

Jun 30, 2021

07:00AM EDT Clene to Host Expert Perspectives Webinar on Cellular Energetic GlobeNewswire Inc

Jun 28, 2021

07:00AM EDT Clene Added to Membership of Russell 2000 Index GlobeNewswire Inc

Jun 15, 2021

07:00AM EDT Clene to Present at the Raymond James Human Health Innovation GlobeNewswire Inc

May 24, 2021

04:28PM EDT Clene Filing Shows Director David J Matlin Purchased 207,684 Shares At Avg. Price Of $9.63 Benzinga

08:02AM EDT Clene Announces Plan to Expand its Manufacturing Capacity of CNM-Au8, Closing of Up to $30M Debt Facility, and Financing Agreements for $9.25M At-the-Market Private Placement Benzinga

08:00AM EDT Clene Announces Plan to Expand its Manufacturing Capacity of GlobeNewswire Inc

May 20, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 20, 2021 Benzinga

09:24AM EDT Maxim Group Initiates Coverage On Clene with Buy Rating, Announces Price Target of $18 Benzinga

May 19, 2021

09:13AM EDT Clene Names David Matlin Chair Benzinga

09:00AM EDT Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, Clene) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to the treatment of neurodegenerative disease using bioenergetic nanocatalysis, today announced the appointment of David J. Matlin as Chairman of the Board. He has served as a Director of Clene since 2020. GlobeNewswire Inc

May 17, 2021

07:00AM EDT International award will fund preclinical study of CNM-Au8 nanocatalysis for the improvement of human health and lifespan in the contexts of aging and Alzheimers disease GlobeNewswire Inc

May 12, 2021

09:07AM EDT Clene Nanomedicine To Present Updated Blinded Efficacy Data From Ongoing Phase 2 RESCUE-ALS Study At The ENCALS 2021 Annual Meeting Benzinga

09:00AM EDT Preliminary blinded efficacy data suggest CNM-Au8 may have the potential for neuro-repair in amyotrophic lateral sclerosis (ALS) patients GlobeNewswire Inc

May 11, 2021

07:31AM EDT Clene Q1 EPS $(0.66) Down From $(0.23) YoY Benzinga

07:00AM EDT Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients GlobeNewswire Inc

May 3, 2021

02:59PM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2021 Benzinga

06:49AM EDT Cantor Fitzgerald Initiates Coverage On Clene with Overweight Rating, Announces Price Target of $22 Benzinga

Apr 30, 2021

07:00AM EDT Clene Nanomedicine Receives Two Patent Notice of Allowances in the GlobeNewswire Inc

Mar 29, 2021

07:06AM EDT Clene Reports FY20 EPS $(1.10) Down From $(0.93) YoY Benzinga

07:00AM EDT Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics GlobeNewswire Inc

Mar 10, 2021

09:00AM EST Clene Nanomedicine Announces Upcoming Presentations at the Maxim GlobeNewswire Inc

Mar 9, 2021

09:18AM EST Clene Nanomedicine Announces Achievement Of 50% Enrollment In Phase 3 HEALEY ALS Platform Trial Benzinga

08:49AM EST Clene Subsidiary Reports Achievement Of 50% Enrollment In Phase 3 HEALEY ALS Platform Trial RTTNews

08:32AM EST Clene Nanomedicine Announces Achievement of 50% Enrollment in the GlobeNewswire Inc

Mar 3, 2021

04:05PM EST Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, Clene) today announced that its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegenerative disease using nanocatalysis, will present at the following upcoming investor conferences: GlobeNewswire Inc

Mar 2, 2021

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For March 2, 2021 Benzinga

09:40AM EST Benchmark Initiates Coverage On Clene with Buy Rating, Announces Price Target of $25 Benzinga

Mar 1, 2021

07:19AM EST Clene Nanomedicine Says Awarded Michael J. Fox Foundation Grant To Accelerate Development Of CNM-Au8 As Treatment For Parkingson's Disease; Size Not Disclosed Benzinga

07:00AM EST -- Interim data from a Phase 2 target engagement study show that CNM-Au8 treatment was associated with improvements across key CNS bioenergetic metabolites in Parkinsons disease patients -- Initiation of a Phase 2 proof-of-concept trial in Parkinsons disease patients expected in 2021 GlobeNewswire Inc

Feb 25, 2021

11:38AM EST Clene's Lead Candidate Shows Improvement In Functional Scores In Multiple Sclerosis Studies Benzinga

08:24AM EST Clene Nanomedicine Says Blended Interim Data From VISIONARY-MS Continue To Support Potential Of CNM-Au8 To 'Drive Meaningful Neurological Improvements In MS Patients,' Says Updated Data To Be Presented At ACTRIMS Forum 2021 Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

07:31AM EST -- Blinded interim data from VISIONARY-MS continue to support the potential of CNM-Au8 to drive meaningful neurological functional improvements in MS patients -- Interim REPAIR-MS results provide further evidence of CNM-Au8s homeostatic effect on brain bioenergetics in MS patients GlobeNewswire Inc

Feb 19, 2021

07:00AM EST Clene Nanomedicine to Present Updated Interim Data from Phase 2 GlobeNewswire Inc

Feb 16, 2021

01:29PM EST Clene To Start Testing CNM-ZnAg In COVID-19 Patients In Brazil Benzinga

07:05AM EST Clene Nanomedicine Initiates Phase 2 Study Of CNM-ZnAg For Patients With COVID-19 Benzinga

07:00AM EST -- Study to evaluate CNM-ZnAg in acutely symptomatic, non-hospitalized COVID-19 patients GlobeNewswire Inc

Feb 3, 2021

10:02AM EST Benzinga's Top Ratings Upgrades, Downgrades For February 3, 2021 Benzinga

08:05AM EST Roth Capital Initiates Coverage On Clene with Buy Rating, Announces Price Target of $24 Benzinga

Jan 19, 2021

07:07AM EST Clene Nanomedicine Receives Patent Notice of Allowance in the United States for using Gold Nanocrystals for the Treatment of Multiple Sclerosis Benzinga

07:00AM EST -- Resulting patenttocovermethods ofusing Clenes lead candidate CNM-Au8, now in Phase 2 and 3 trials for Multiple Sclerosis (MS) and Amyotrophic lateral sclerosis (ALS) -- Latest patent allowance adds to Clenes robust IP estate including over 130 patents issued and pending applications GlobeNewswire Inc

Dec 30, 2020

05:38PM EST Common stock of the merged company, Clene Inc., to commence trading on the NASDAQ Capital Market under the ticker symbol CLNN on December 31, 2020 GlobeNewswire Inc

.dark-mode .n620CW{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .n620CW{ color: #333333; background-color: white; border: 2px solid #333333; }CLNNClene Inc. Common Stockstock NASDAQ

CLNN
Clene Inc. Common Stock
stock NASDAQ